

Rik Ossenkoppele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7939807/publications.pdf>

Version: 2024-02-01

274
papers

13,064
citations

34493

54
h-index

32181

105
g-index

329
all docs

329
docs citations

329
times ranked

10752
citing authors

#	ARTICLE	IF	CITATIONS
1	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster A β -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 103-115.	0.4	24
2	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2022, 269, 1375-1385.	1.8	23
3	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	4.9	203
4	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1951-1963.	3.3	8
5	Research Criteria for the Behavioral Variant of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 48.	4.5	44
6	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
7	Genetically identical twins show comparable tau PET load and spatial distribution. <i>Brain</i> , 2022, 145, 3571-3581.	3.7	12
8	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. <i>Journal of Nuclear Medicine</i> , 2022, 63, 981-985.	2.8	9
9	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 149.	4.5	66
10	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2022, 98, .	1.5	49
11	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. <i>Neurology</i> , 2022, 98, .	1.5	17
12	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 48.	3.0	42
13	The protective gene dose effect of the <i>APOE</i> ϵ 2 allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13
14	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
15	Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. <i>Lancet Neurology</i> , The, 2022, 21, 726-734.	4.9	130
16	Tau PET Imaging in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 20S-26S.	2.8	26
17	Biweekly fluctuations of neuropsychiatric symptoms according to the Neuropsychiatric Inventory: Erratic symptoms or scores?. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
18	Does Loss of Integrity of the Cingulum Bundle Link Amyloid- β Accumulation and Neurodegeneration in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 39-49.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β^2 negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021, 97, 41-48.	1.5	23
20	Untangling the association of amyloid- β^2 and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	3.7	123
21	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2245-2258.	3.3	27
22	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. <i>Cerebral Cortex</i> , 2021, 31, 1-14.	1.6	34
23	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 604-613.	1.3	10
24	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 30, 102660.	1.4	13
25	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.	1.3	2
26	In vivo tau pathology is associated with synaptic loss and altered synaptic function. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 35.	3.0	47
27	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120.	3.3	33
28	Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia. <i>Scientific Reports</i> , 2021, 11, 4168.	1.6	9
29	Differential associations of APOE- ϵ^2 and APOE- ϵ^4 alleles with PET-measured amyloid- β^2 and tau deposition in older individuals without dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2212-2224.	3.3	29
30	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2021, 17, 1186-1194.	0.7	4
31	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. <i>Neurocase</i> , 2021, 27, 181-189.	0.2	2
32	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2086-2096.	3.3	11
33	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	3.3	22
34	Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 871-881.	15.2	354
35	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 872-880.	0.9	17
36	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1998-2008.	0.4	25

#	ARTICLE	IF	CITATIONS
37	A multicenter comparison of [¹⁸ F]flortaucipir, [¹⁸ F]RO948, and [¹⁸ F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2295-2305.	3.3	41
38	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. <i>Neurology</i> , 2021, 97, 474-488.	1.5	46
39	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.5	16
40	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	3.3	58
41	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 138.	3.0	10
42	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, e1276-e1287.	1.5	44
43	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	4.5	148
44	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 31, 102725.	1.4	9
45	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2259-2271.	3.3	10
46	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster A β -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
47	Ability of tau-PET, phospho-tau217, NfL and cortical thickness to predict short-term cognitive decline in early symptomatic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
48	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: A meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
49	Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
50	Longitudinal [¹⁸ F]flortaucipir PET: Comparison of quantitative and semi-quantitative parameters. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
51	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
52	Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimer's disease dementia: The Amyloid Biomarker Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
53	Residual approaches to capture resilience and resistance in aging and Alzheimer's disease: A meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
54	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
55	[¹⁸ F]RO948 tau PET in bvFTD due to <i>C9orf72</i> and <i>GRN</i> mutations. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
56	A data-driven latent atrophy factor model reveals differential associations between relative frontal atrophy patterns and specific neuropsychiatric symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
57	Tau PET as a prognostic marker in preclinical and prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
58	Associations between the <i>APOE</i> _{ε2} and <i>APOE</i> _{ε4} alleles with resistance and resilience against Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, e051346.	0.4	0
59	Parametric methods for [¹⁸ F]flortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 365-373.	2.4	22
60	Test-retest repeatability of [¹⁸ F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2464-2474.	2.4	23
61	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.4	73
62	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. <i>NeuroImage: Clinical</i> , 2020, 25, 102113.	1.4	5
63	Why Is Amyloid- β PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	1.2	8
64	Amyloid- β -independent regulators of tau pathology in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2020, 21, 21-35.	4.9	338
65	Comorbid amyloid- β pathology affects clinical and imaging features in VCD. <i>Alzheimer's and Dementia</i> , 2020, 16, 354-364.	0.4	6
66	Amyloid- β PET and CSF in an autopsy-confirmed cohort. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2150-2160.	1.7	17
67	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254
68	Derivation and utility of an β -PET pathology accumulation index to estimate β load. <i>Neurology</i> , 2020, 95, e2834-e2844.	1.5	14
69	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020, 95, e1672-e1685.	1.5	19
70	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 148.	3.0	17
71	Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1519-1546.	1.2	27
72	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	4.7	86

#	ARTICLE	IF	CITATIONS
73	Association of amyloid- β CSF/PET discordance and tau load 5 years later. <i>Neurology</i> , 2020, 95, e2648-e2657.	1.5	33
74	Association between APOE ϵ 2 and ϵ 4 burden in patients with Alzheimer- and vascular-type cognitive impairment. <i>Neurology</i> , 2020, 95, e2354-e2365.	1.5	4
75	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.	3.7	76
76	Development and validation of language and visuospatial composite scores in ADNI. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12072.	1.8	29
77	Amyloid- β CSF/PET discordance vs tau load 5 years later: It takes two to tangle. <i>Alzheimer's and Dementia</i> , 2020, 16, e037246.	0.4	0
78	Alzheimer's disease biomarker roadmap 2020: [18 F]flortaucipir. <i>Alzheimer's and Dementia</i> , 2020, 16, e039550.	0.4	0
79	Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039556.	0.4	1
80	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557.	0.4	2
81	Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid- β and tau deposition in older individuals without dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e040440.	0.4	1
82	Accounting for systematic spatiotemporal variation improves connectome-based models of tau spreading in human Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040586.	0.4	0
83	Modeling patient-specific tau spreading patterns in Alzheimer's disease: Towards precision medicine. <i>Alzheimer's and Dementia</i> , 2020, 16, e040587.	0.4	2
84	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041048.	0.4	2
85	Early-onset Alzheimer's disease is related to differential spatial patterns of tau pathology and cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042041.	0.4	0
86	Predictors of preclinical Alzheimer's disease in persons with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e042658.	0.4	1
87	The accumulation rate of tau aggregates is higher in females and younger individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e043876.	0.4	2
88	Heterogeneous distribution of pathology in behavioral variant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044830.	0.4	1
89	Diagnosis and management of neuropsychiatric symptoms in early Alzheimer's disease in the memory clinic setting. <i>Alzheimer's and Dementia</i> , 2020, 16, e045061.	0.4	0
90	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045236.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Development and validation of composite scores for language and visuospatial functioning in ADNI. <i>Alzheimer's and Dementia</i> , 2020, 16, e045508.	0.4	0
92	The effects of mesial temporal tau in Ab ⁻ negative cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045607.	0.4	0
93	Quantitative accuracy remains after shortening of dynamic [18 F]flortaucipir PET protocol. <i>Alzheimer's and Dementia</i> , 2020, 16, e045710.	0.4	0
94	Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045770.	0.4	0
95	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18 F]flortaucipir, [11 C]UCB ⁺ and magnetoencephalography study. <i>Alzheimer's and Dementia</i> , 2020, 16, e045806.	0.4	0
96	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045876.	0.4	0
97	The biomarker roadmap for the validation for Alzheimer's biomarkers: Methodological update for biomarkers of tauopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e039063.	0.4	3
98	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.4	3
99	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , 2020, 77, 955.	4.5	136
100	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3165-3175.	3.3	28
101	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. <i>Brain</i> , 2020, 143, 1233-1248.	3.7	164
102	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 632.	4.5	80
103	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 347.	5.8	185
104	A ^β deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	4.7	202
105	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	3.3	29
106	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020, 143, 3805-3815.	3.7	65
107	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 118.	3.0	129
108	[11C]PIB amyloid quantification: effect of reference region selection. <i>EJNMMI Research</i> , 2020, 10, 123.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043169.	0.4	1
110	Cognitive reserve and clinical progression in Alzheimer disease. <i>Neurology</i> , 2019, 93, e334-e346.	1.5	85
111	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
112	Associations between quantitative [18F]florotau PET and atrophy across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 60.	3.0	40
113	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.5	51
114	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.4	18
115	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	3.0	40
116	Amyloid- β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 7.	1.7	37
117	Predicting diagnosis and cognition with ^{18}F -AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 570-580.	0.4	84
118	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 48.	3.0	14
119	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. <i>NeuroImage: Clinical</i> , 2019, 23, 101848.	1.4	73
120	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. <i>Cerebral Cortex</i> , 2019, 29, 2173-2182.	1.6	39
121	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019, 79, 50-58.	1.5	41
122	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 383-394.	1.2	14
123	Mechanisms underlying resilience in ageing. <i>Nature Reviews Neuroscience</i> , 2019, 20, 246-246.	4.9	34
124	ICA100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P87.	0.4	0
125	F201: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P515.	0.4	0
126	ICA079: SPATIAL DISTRIBUTION AND TOPOGRAPHICAL RELATIONSHIPS OF PATHOLOGY AND NEURODEGENERATION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P71.	0.4	0

#	ARTICLE	IF	CITATIONS
127	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P68.	0.4	0
128	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. Alzheimer's and Dementia, 2019, 15, P84.	0.4	0
129	PET and CSF amyloid- β^2 status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	3.0	21
130	Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar?. NeuroImage: Clinical, 2019, 21, 101628.	1.4	22
131	Associations between tau, $A\beta^2$, and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.5	196
132	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
133	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	2.8	57
134	Evidence-based Interpretation of Amyloid- β^2 PET Results. Alzheimer Disease and Associated Disorders, 2018, 32, 28-34.	0.6	28
135	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.1	41
136	Prevalence of the apolipoprotein E ϵ^4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
137	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	1.4	126
138	Association of Cerebral Amyloid- β^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
139	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology, 2018, 90, e149-e156.	1.5	103
140	O3â€13â€01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1054.	0.4	0
141	P3â€413: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1263.	0.4	0
142	ICâ€Pâ€222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.4	0
143	O2â€04â€02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P621.	0.4	0
144	P2â€153: DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P726.	0.4	0

#	ARTICLE	IF	CITATIONS
145	P2â€³60: [¹⁸ F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.4	0
146	O2â€³03â€³03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P615.	0.4	0
147	O2â€³06â€³01: [¹⁸ F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P630.	0.4	0
148	ICâ€³Pâ€³178: COMPARING HIPPOCAMPAL EFFECT SIZE BETWEEN ALZHEIMER'S DISEASE AND HEALTHY CONTROLS USING OLDER AND NEWER VERSIONS OF SPM AND FREESURFER. Alzheimer's and Dementia, 2018, 14, P150.	0.4	0
149	O2â€³09â€³06: FREQUENCIES OF CEREBROSPINAL FLUID A/T/N BIOMARKER PROFILES AND THEIR ASSOCIATION WITH MEMORY FUNCTION IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
150	ICâ€³Pâ€³192: DISEASEâ€³STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P158.	0.4	2
151	ICâ€³Pâ€³224: HETEROGENEOUS TAUâ€³PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P182.	0.4	0
152	ICâ€³Pâ€³110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.4	0
153	P2â€³291: THE DIAGNOSTIC CHALLENGE OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE: A CASE REPORT. Alzheimer's and Dementia, 2018, 14, P792.	0.4	0
154	F5â€³05â€³04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1633.	0.4	0
155	P1â€³467: DISEASEâ€³STAGEâ€³SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P500.	0.4	0
156	P1â€³430: EFFECTS OF <i>APOE</i> ϵ 4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.4	0
157	P3â€³877: COMPARING HIPPOCAMPAL EFFECT SIZE BETWEEN ALZHEIMER'S DISEASE AND HEALTHY CONTROLS USING OLDER AND NEWER VERSIONS OF SPM AND FREESURFER. Alzheimer's and Dementia, 2018, 14, P1236.	0.4	0
158	P3â€³585: COGNITIVE RESERVE MODULATES THE ASSOCIATION OF CEREBRAL AMYLOID PATHOLOGY WITH COGNITIVE PERFORMANCE IN PERSONS WITH ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1349.	0.4	0
159	F1â€³04â€³01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€³DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P206.	0.4	0
160	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	1.1	19
161	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimerâ€³s Disease: A Case Report. Journal of Alzheimer's Disease, 2018, 66, 1363-1369.	1.2	5
162	O3â€³04â€³01: ASSOCIATIONS BETWEEN TAU, A β 2 AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1018.	0.4	0

#	ARTICLE	IF	CITATIONS
163	ICâ€œPâ€œ036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€œDEMENTED ELDERLY SUBJECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P39.	0.4	0
164	Genetic characterization of amyloid- β^2 and tau network spread. <i>Nature Medicine</i> , 2018, 24, 1790-1792.	15.2	1
165	Prevalence of amyloidâ€œ β^2 pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
166	Clinical phenotype, atrophy, and small vessel disease in $\langle i \rangle$ APOE $\langle /i \rangle$ $\hat{\mu}2$ carriers with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1851-e1859.	1.5	46
167	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	3.8	298
168	Is intracranial volume a suitable proxy for brain reserve?. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 91.	3.0	54
169	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 625-632.	1.4	23
170	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 71-77.	1.2	2
171	Molecular imaging in dementia: Past, present, and future. <i>Alzheimer's and Dementia</i> , 2018, 14, 1522-1552.	0.4	68
172	Greater tau load and reduced cortical thickness in APOE $\hat{\mu}4$ -negative Alzheimerâ€œ™s disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	3.0	56
173	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	4.5	102
174	Quantification of Tau Load in Alzheimerâ€œ™s Disease Clinical Trials Using Positron Emission Tomography. <i>Methods in Molecular Biology</i> , 2018, 1750, 221-229.	0.4	1
175	Frontotemporal dementia with the V337M $\langle i \rangle$ MAPT $\langle /i \rangle$ mutation. <i>Neurology</i> , 2017, 88, 758-766.	1.5	76
176	Quantification of Tau Load Using [18F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	1.3	42
177	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.	1.9	59
178	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. <i>European Radiology</i> , 2017, 27, 4237-4246.	2.3	37
179	The Complexity of Subjective Cognitive Decline. <i>JAMA Neurology</i> , 2017, 74, 1400.	4.5	15
180	Clinicopathological correlations in behavioural variant frontotemporal dementia. <i>Brain</i> , 2017, 140, 3329-3345.	3.7	226

#	ARTICLE	IF	CITATIONS
181	[P1â€“311]: THE ROLE OF NEUROPSYCHIATRIC SYMPTOMS IN AD DIFFERENTIAL DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P372.	0.4	2
182	[P2â€“388]: INTRINSIC CONNECTIVITY NETWORKS IN POSTERIOR CORTICAL ATROPHY: A ROLE FOR THE PULVINAR?. Alzheimer's and Dementia, 2017, 13, P778.	0.4	0
183	[P2â€“407]: PREVALENCE OF AMYLOIDâ€PET POSITIVITY ACCORDING TO AGE AND <i>APOE</i> GENOTYPE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P787.	0.4	0
184	[P3â€“407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1120.	0.4	0
185	[P4â€“197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.4	0
186	[P4â€“219]: [¹⁸ F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1352.	0.4	0
187	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.4	0
188	[ICâ€Pâ€005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€ ² AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.4	1
189	[ICâ€Pâ€031]: INTRINSIC CONNECTIVITY NETWORKS IN POSTERIOR CORTICAL ATROPHY: A ROLE FOR THE PULVINAR?. Alzheimer's and Dementia, 2017, 13, P28.	0.4	0
190	[ICâ€Pâ€037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P33.	0.4	0
191	[ICâ€Pâ€055]: EFFECT OF APOEâ€ ² ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.4	0
192	[ICâ€Pâ€106]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.	0.4	0
193	[ICâ€Pâ€203]: [¹⁸ F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.	0.4	0
194	[ICâ€Pâ€206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.4	0
195	[P1â€“575]: PREVALENCE OF THE APOLIPOPROTEIN E ⁴ ALLELE IN AMYLOIDâ€ ² POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	0.4	0
196	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€ ² AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.4	0
197	[P2â€“335]: EFFECT OF APOE ² ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
198	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.4	0

#	ARTICLE	IF	CITATIONS
199	[F4â€“01â€“01]: PET AND MRI STUDIES IN ATYPICAL VARIANTS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1210.	0.4	0
200	[DTâ€“01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.4	0
201	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. Brain, 2017, 140, 2286-2294.	3.7	149
202	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	1.4	62
203	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology, 2016, 281, 865-875.	3.6	58
204	ICâ€“Pâ€“196: Quantification of TAU Load Using [¹⁸ F]AVâ€“1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
205	P1â€“178: Impact of Coâ€“Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.4	0
206	P1â€“1818: TAUâ€“PET Patterns Overlap and Exceed Hypometabolism in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P545.	0.4	2
207	ICâ€“Pâ€“097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P74.	0.4	0
208	ICâ€“Pâ€“103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€“Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0
209	ICâ€“Pâ€“181: TAUâ€“PET Patterns Overlap and Exceed Hypometabolism in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P132.	0.4	1
210	P4â€“191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.4	0
211	P4â€“215: Quantification of Tau Load Using [¹⁸ F]AVâ€“1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.4	0
212	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0
213	O1-07-05: Longitudinal Patterns of Cerebral Atrophy in Distinct Clinical Variants of Alzheimerâ€™s Disease. , 2016, 12, P191-P193.		1
214	O1-11-03: Prevalence of Amyloid-b Pathology in Primary Progressive Aphasia Variants: A Multicenter Study. , 2016, 12, P202-P203.		0
215	O3â€“08â€“04: Tau Covariance Patterns in Alzheimer's Disease Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P305.	0.4	0
216	O3-09-02: Cognitive Consequences of Cerebral Amyloid Pathology in Persons without Dementia. , 2016, 12, P307-P308.		0

#	ARTICLE	IF	CITATIONS
217	PET Imaging of Tau Deposition in the Aging Human Brain. <i>Neuron</i> , 2016, 89, 971-982.	3.8	899
218	ICâ€Pâ€192: TAU Covariance Patterns in ad Patients Resemble Intrinsic Connectivity Networks in Young Adults. <i>Alzheimer's and Dementia</i> , 2016, 12, P138.	0.4	0
219	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimerâ€™s disease. <i>Brain</i> , 2016, 139, 1551-1567.	3.7	833
220	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. <i>Brain Connectivity</i> , 2016, 6, 1-8.	0.8	18
221	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
222	IC-02-03: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P6-P6.		0
223	IC-02-02: Distinct [18 F]AV1451 retention patterns in clinical variants of Alzheimer's disease. , 2015, 11, P5-P6.		1
224	O4-01-02: Associations of [18 F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer's disease. , 2015, 11, P265-P266.		1
225	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
226	IC-P-157: Associations of [18 F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer's disease. , 2015, 11, P105-P106.		0
227	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. <i>Annals of Neurology</i> , 2015, 77, 338-342.	2.8	124
228	Prediction of AD dementia by biomarkers following the NIAâ€™AA andâ€™IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015, 11, 1191-1201.	0.4	71
229	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	1.9	196
230	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
231	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
232	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
233	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
234	F2-03-01: Tau and amyloid neuroimaging of ad phenotypes. , 2015, 11, P167-P167.		0

#	ARTICLE	IF	CITATIONS
235	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2340-2347.	1.5	49
236	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.	3.7	397
237	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015, 25, 3050-3059.	2.3	80
238	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
239	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	3.8	501
240	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
241	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1177.	3.8	6
242	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnesic MCI: An European Alzheimer's Disease Consortium (EADC) Project. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 815-826.	1.2	67
243	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e102995.	1.1	56
244	Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function?. <i>Cerebral Cortex</i> , 2014, 24, 2210-2218.	1.6	36
245	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.	1.5	51
246	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.	1.9	37
247	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1190-8.	3.3	7
248	Comparison of Simplified Parametric Methods for Visual Interpretation of ¹¹ C-Pittsburgh Compound-B PET Images. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1305-1307.	2.8	24
249	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 801-807.	1.2	109
250	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
251	P2-194: PREVALANCE OF AMYLOID IN DEMENTED SUBJECTS. , 2014, 10, P542-P543.		0
252	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0

#	ARTICLE	IF	CITATIONS
253	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
254	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
255	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
256	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA-TWO SIDES OF THE SAME COIN?. , 2014, 10, P543-P543.		1
257	O3-06-04: EFFECT OF APOE GENOTYPE ON THE PREVALENCE OF AMYLOID PATHOLOGY IN NON-DEMENTED SUBJECTS. , 2014, 10, P220-P220.		0
258	IC-P-010: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P12-P12.		1
259	Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. , 2014, , 185-211.		1
260	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.4	159
261	Amyloid imaging in clinical trials. Alzheimer's Research and Therapy, 2013, 5, 36.	3.0	18
262	S1-02-03: Mild cognitive impairment associated with nonamyloid biomarker findings. , 2013, 9, P122-P122.		0
263	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	2.8	108
264	Differential effect of <i>APOE</i> genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.	1.5	99
265	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161
266	Longitudinal Amyloid Imaging Using ¹¹ C-PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.	2.8	148
267	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain, 2012, 135, 2115-2125.	3.7	109
268	O4-03-01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.4	0
269	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	1.5	108
270	Longitudinal imaging of Alzheimer pathology using [11C]PiB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 990-1000.	3.3	145

#	ARTICLE	IF	CITATIONS
271	Amyloid imaging in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 26.	3.0	23
272	Disease Progression Course from Preclinical Stages of Alzheimer's Disease to Dementia: Distinct Progression by Sex and Apoe ϵ 4. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
273	Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?. <i>Brain</i> , 0, , .	3.7	0
274	The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians. <i>Psychogeriatrics</i> , 0, , .	0.6	4